CHILDHOOD ABSENCE EPILEPSY: RX, PK-PD-PHARMACOGENETICS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标1a：采用无失败试验设计，确定乙琥胺(ETX)、拉莫三嗪(LTG)或丙戊酸(VPA)是治疗儿童失神癫痫(CAE)的最有效的初始单一疗法。CAE被定义为具有最大可能控制癫痫发作且随着时间的推移限制副作用的治疗风险最低的抗癫痫药物(AED)。 具体目标1b：明确和对比ETX、LTG和VPA单一治疗对CAE儿童认知(特别是注意力)、行为和生活质量的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aim 1a: To determine whether ethosuximide (ETX), lamotrigine (LTG) or valproic acid (VPA) is the most effective initial monotherapy for pediatric subjects with childhood absence epilepsy (CAE), defined as the antiepileptic drug (AED) with the greatest likelihood of seizure control and lowest risk of treatment limiting side effects over time, using a freedom from failure trial design. Specific Aim 1b: To define and contrast the effects of ETX, LTG, and VPA monotherapy on cognition (especially attention), behavior and quality of life in children with CAE.